Loading...
01/11 16:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial management, with reduced financial expenses and a gain from discontinued operations. The Q&A session reveals positive developments like the approval of new diabetes products and plans for market expansion in Africa. While there are some uncertainties, such as the timeline for CGM revenue, the overall sentiment is optimistic with expected revenue growth, cost-saving initiatives, and strategic market positioning. These factors suggest a positive stock price movement.
Q4 2023 Revenue $13.4 million, a decline of $2.3 million (approximately 15%) year-over-year due to declines in hemoglobin business, autoimmune business, and COVID-19 VTM products.
Q4 2023 Gross Profit $4.6 million, gross margin percentage of 34%, consistent with Q4 2022.
Q4 2023 SG&A Expenses $6.9 million, a decrease of $2.8 million (approximately 29%) year-over-year, primarily due to lower share-based payments expense related to former CEO's resignation.
Q4 2023 Operating Loss $3.8 million, improved from $8.2 million in Q4 2022, driven by lower impairment charges and lower SG&A expenses.
Q4 2023 Cash Balance $3.7 million, decreased from $6.3 million in Q3 2023.
Full Year 2023 Revenue $56.8 million, a decrease of approximately 9% year-over-year, driven by lower COVID revenues, autoimmune lab services revenues, and declines in hemoglobin business.
Full Year 2023 Gross Margin $19.5 million, gross margin percentage of 34.2%, an increase of 6.6% year-over-year due to a significant inventory obsolescence charge in Q3 2022.
Full Year 2023 SG&A Expenses $31.2 million, an increase of $4.2 million (approximately 16%) year-over-year, driven by higher technical advisory, legal, and professional fees related to the acquisition of biosensor assets.
Full Year 2023 Operating Loss $27 million, reflecting ongoing challenges in revenue generation.
Full Year 2023 Cash Used by Operations $11.9 million, inclusive of a negative net movement in working capital of $2.7 million.
Full Year 2023 Profit from Discontinued Operations $12.9 million, largely from the divestiture of Fitzgerald Industries.
Full Year 2023 Financial Expenses $11.1 million, a decrease from $24.7 million in FY’22, primarily due to the absence of significant losses related to exchangeable notes and lower early repayment penalties.
Full Year 2023 Impairment Charges $11.1 million, largely driven by impairment to Immco due to loss of revenue from transplant testing.
New Product Launch: Trinity Biotech plans to launch a more affordable, high-quality continuous glucose monitor (CGM) as part of their newly acquired biosensor technology from Waveform Technologies.
Product Development: The new diabetes HbA1c Column System has been developed and tested, delivering up to four times the number of injections compared to the existing product, with a commercial launch expected in Q2 2024.
Market Expansion: Trinity Biotech aims to build a global business in wearable biosensors, focusing initially on CGMs, which are expected to be a key growth driver.
New Market Entry: The company has begun sales of its TrinScreen product in Africa, which is anticipated to be a significant growth driver.
Operational Efficiency: Trinity Biotech plans to cease manufacturing at its Kansas site by the end of 2024, aiming for multi-million dollar annualized operational efficiencies.
Cost Reduction: The company is negotiating supplier changes to reduce the cost of goods, already achieving millions in annualized savings.
Strategic Shift: Trinity Biotech is undergoing a comprehensive transformation plan to improve financial performance and streamline operations, targeting $20 million in annualized run-rate EBITDASO by Q2 2025.
Acquisition Strategy: The acquisition of Waveform Technologies' biosensor technology is a strategic move to enter the rapidly expanding CGM market.
Regulatory Issues: The company is monitoring a legal challenge against the Kenyan government regarding the HIV testing algorithm, which could impact orders for their TrinScreen HIV tests.
Supply Chain Challenges: Trinity Biotech is experiencing declines in revenue from their hemoglobin business due to renegotiation of contract terms, which has led to deferred shipments.
Competitive Pressures: The company faces competition in the CGM market, which necessitates the development of a highly competitive product to capture market share.
Economic Factors: The company reported a decrease in revenues for Q4 2023 and full year 2023, attributed to lower sales in various segments, including COVID-19 products and autoimmune lab services.
Operational Risks: The company is undergoing significant transformation initiatives, which involve consolidating manufacturing operations and outsourcing, presenting execution risks that need to be managed carefully.
Financial Risks: The company has a high operating loss and is reliant on external funding, with a recent amendment to their credit agreement to secure additional liquidity for operations and development.
Annualized Run-Rate EBITDASO Target: Targeting approximately $20 million of annualized run-rate EBITDASO by Q2, 2025.
Annualized Run-Rate Revenue Target: Targeting approximately $75 million of annualized run-rate revenues by Q2, 2025.
Biosensor Business Growth: Aiming to build a global business in wearable biosensors, focusing on continuous glucose monitors (CGMs).
Acquisition of Waveform Technologies: Acquired biosensor technology from Waveform Technologies, including a European Regulatory Approved CGM product.
Manufacturing Consolidation: Ceasing manufacturing at the Kansas site by the end of 2024 to create multi-million dollar annualized operational efficiency.
Cost Reduction Initiatives: Reducing cost of goods through supplier negotiations and changes, targeting millions in annualized savings.
Simplification of Operations: Centralizing business support functions in lower-cost locations to reduce SG&A expenditure.
2024 Outlook: 2024 is off to a strong start, increasing confidence in the outlook.
Financial Performance Improvement: Focused on improving financial performance of existing business to generate substantial free cash flow.
Future Financial Benefits: Expecting financial benefits from new diabetes HbA1c Column System rollout from Q2 2024.
Liquidity and Funding: Amended credit agreement provides additional liquidity of up to $6.5 million for CGM and biosensor development.
Shareholder Return Plan: Trinity Biotech is focused on generating substantial free cash flow from its existing business, which is a key component of its transformation plan aimed at enhancing shareholder value. The company is targeting approximately $20 million of annualized run-rate EBITDASO by Q2 2025, based on targeted annualized run-rate revenues of approximately $75 million. Additionally, the company is implementing cost-saving measures, including a $4 million annualized savings from operational efficiencies, which will contribute to improved profitability and cash flow generation.
The earnings call reveals mixed signals. Financial performance shows improvement in losses and revenue growth in key areas, but there are ongoing financial challenges, competitive pressures in the CGM market, and operational risks due to restructuring. The lack of a clear shareholder return plan and unclear management responses in the Q&A add uncertainty. Despite positive revenue growth in TrinScreen HIV and cost reduction efforts, the net loss and financial risks limit optimism, resulting in a neutral stock price prediction.
The earnings call summary presents a mixed outlook: strong growth in point-of-care revenues and improved financial health, but challenges like restructuring costs, competitive pressures, and lack of shareholder returns. The Q&A section suggests some uncertainties, particularly with the CGM trials and new Premier instruments. Despite positive elements, such as potential growth in clinical chemistry and a new distribution partner, the absence of clear guidance and shareholder return plans tempers optimism, resulting in a neutral sentiment.
The earnings call presents a mixed picture. While there are improvements in operating and net losses, and revenue growth in the Point-of-Care business, the company faces challenges such as declining clinical laboratory revenues and high debt levels. The Q&A reveals management's reluctance to provide specific details, which may concern investors. Overall, the financial performance and business updates are balanced, leading to a neutral sentiment.
The earnings call highlights strong financial management, with reduced financial expenses and a gain from discontinued operations. The Q&A session reveals positive developments like the approval of new diabetes products and plans for market expansion in Africa. While there are some uncertainties, such as the timeline for CGM revenue, the overall sentiment is optimistic with expected revenue growth, cost-saving initiatives, and strategic market positioning. These factors suggest a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
